Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly Crinetics Pharmaceuticals (Nasdaq: CRNX) submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY (paltusotine) to treat acromegaly in adults on March 26, 2026. The filing is supported by data from 18 clinical trials, including two Phase 3 studies that met all primary and secondary endpoints. PALSONIFY is already approved in the US and recently received a positive CHMP opinion in Europe.

#CRNX Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

www.stocktitan.net/news/CRNX/crinetics-phar...

Crinetics Pharma COO to Step Down, Shares Weaken Crinetics announced a COO departure on Mar 23, 2026; Nasdaq-listed CRNX saw elevated intraday volume and volatility, per Seeking Alpha and exchange data.

Crinetics Pharma COO to Step Down, Shares Weaken: Crinetics announced a COO departure on Mar 23, 2026; Nasdaq-listed CRNX saw elevated intraday volume and volatility, per Seeking Alpha and exchange data. 👈 Read full analysis #CrineticsPharma #COO #Nasdaq #CRNX #PharmaNews

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Crinetics Pharmaceuticals (Nasdaq: CRNX) reported Q4 and full-year 2025 results highlighting the commercial launch of PALSONIFY, with $5.4M net product revenue in Q4 and total revenue of $7.7M for 2025. Cash totaled $1.0B at year-end; a Jan 8, 2026 offering added ~$380M. Management expects 2026 GAAP operating expenses of $600–$650M and non-GAAP operating expenses of $480–$520M. Key clinical milestones include EMA CHMP positive opinion for PALSONIFY and initiation plans for an atumelnant Phase 2/3 study in H1 2026.

#CRNX Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CRNX/crinetics-phar...

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) Crinetics (Nasdaq: CRNX) announced dosing of the first patient in the BALANCE-CAH Phase 2/3 trial of atumelnant, a once-daily oral ACTH receptor antagonist for children and adolescents with classic congenital adrenal hyperplasia (CAH).The potential registrational study will assess safety, efficacy, and pharmacokinetics across three parts: Phase 2 dose-ranging (Part A), Phase 3 double-blind randomized placebo-controlled confirmatory (Part B), and an open-label extension (Part C). The drug holds U.S. orphan drug designation for classic CAH.

#CRNX Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

www.stocktitan.net/news/CRNX/crinetics-init...

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock Crinetics Pharmaceuticals (Nasdaq: CRNX) priced an underwritten public offering of 7,620,000 common shares at $45.95 per share, generating gross proceeds of approximately $350 million. The underwriters have a 30-day option to purchase an additional 1,143,000 shares. The offering is expected to close on or about January 8, 2026, subject to customary closing conditions.Crinetics intends to use net proceeds, together with existing cash and investments, to fund the commercial launch of PALSONIFY, research and development of product candidates, other research programs, general corporate purposes, and potentially in-license or acquire complementary assets, although no commitments currently exist. Joint bookrunning managers include Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler, and Cantor; Baird is lead manager.

#CRNX Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

www.stocktitan.net/news/CRNX/crinetics-phar...

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it

#CRNX Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/CRNX/crinetics-phar...

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) Crinetics (Nasdaq: CRNX) announced dosing of the first patient in the CALM-CAH Phase 3 trial of atumelnant on December 11, 2025. The randomized, placebo-controlled adult study will evaluate atumelnant’s ability to reduce excess adrenal androgens and lower glucocorticoid use while assessing other clinical outcomes that reflect disease control.Atumelnant is described as the first-and-only small-molecule ACTH receptor antagonist in late-stage clinical development for classic congenital adrenal hyperplasia (CAH). Phase 2 data showed rapid, sustained reductions in biomarkers including androstenedione and 17-hydroxyprogesterone, plus clinical measures such as adrenal size and resumption of menses. Atumelnant has also received FDA Orphan Drug designation for classic CAH.

#CRNX Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

www.stocktitan.net/news/CRNX/crinetics-anno...

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors Crinetics (Nasdaq: CRNX) announced the first patient has been dosed in the Phase 1/2 BRAVESST2 trial evaluating CRN09682 for metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors and other SST2-expressing tumors on Dec 3, 2025.CRN09682 is the lead candidate from Crinetics’ proprietary nonpeptide drug conjugate (NDC) platform, designed for selective SST2 binding, rapid receptor internalization, and intratumoral release of a cytotoxic payload. The first-in-human, open-label study will assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity across dose-escalation and dose-expansion phases, enrolling up to 150 participants with SST2 confirmation by somatostatin receptor imaging.

#CRNX Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

www.stocktitan.net/news/CRNX/crinetics-anno...

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX)

#CRNX Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

www.stocktitan.net/news/CRNX/crinetics-anno...

#CRNX Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CRNX/crinetics-phar...

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting Crinetics (Nasdaq: CRNX) will present three abstracts at the North American Neuroendocrine Tumor Society Annual Meeting (NANETS 2025), October 23-25, 2025, in Austin, Texas.Key highlights include a preliminary, investigator-assessed one-year progression-free survival (PFS) rate of 74% from an open-label Phase 2 study of paltusotine for carcinoid syndrome and poster details on the randomized Phase 3 CAREFNDR study of paltusotine and the first-in-human study of nonpeptide drug conjugate CRN09682. Paltusotine is marketed in the U.S. as PALSONIFY for acromegaly but is not approved for carcinoid syndrome.

#CRNX Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

www.stocktitan.net/news/CRNX/crinetics-to-h...

Just In: ( NASDAQ: #CRNX ) Is Crinetics Pharmaceuticals Stock a Buy?

Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday - Robo.ai (NASDAQ:AIIO), Aquestive Therapeutics (NASDAQ:AQST) U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA approved PALSONIFY.

Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shar...

#AIIO #AQST #ASM #BB #big #gainers #CRNX #CRS #GRRR #Mid #Day

Origin | Interest | Match

12 Health Care Stocks Moving In Friday's Pre-Market Session - bioAffinity Technologies (NASDAQ:BIAF), Clearside Biomedical (NASDAQ:CLSD) Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.

12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers bioAffinity Technologies (NASDAQ: BIAF ) stock increased by 71.8% to $5.86 during Friday's pre-market session. The compan...

#BIAF #BZI-TFM #CLSD #CRNX #DRIO #GUTS #MDCX #NLSP #ORGO #Penny #Stocks

Origin | Interest | Match

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly Crinetics Pharmaceuticals (Nasdaq: CRNX) has received FDA approval for PALSONIFY™ (paltusotine), marking a significant breakthrough as the first once-daily, oral treatment for adults with acromegaly. The approval is based on successful results from two Phase 3 trials, PATHFNDR-1 and PATHFNDR-2, where the drug demonstrated rapid onset, reliable biochemical control, and sustained efficacy.The drug is specifically approved for adults with acromegaly who had inadequate response to surgery or for whom surgery isn't an option. Clinical trials showed significant symptom reduction and strong safety profile, with 91% and 97% of patients from respective trials enrolling in the open-label extension. PALSONIFY will be available in the U.S. in early October 2025, supported by CrinetiCARE®, a comprehensive patient support program.

#CRNX Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

www.stocktitan.net/news/CRNX/crinetics-anno...

From Injections to Pills: Why Crinetics (CRNX) Could Be Biotech’s Next Breakout Paltusotine Positions Crinetics as a Potential Endocrine Market Disruptor Amid Biotech’s Risk-On Recovery

$CRNX is aiming to disrupt a $1.6B market with oral Paltusotine. First oral alternative in acromegaly could reshape endocrinology. Full Signal Pathway deep dive signalpathway.substack.com/p/from-injec... #Biotech #CRNX #BiotechStocks

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH) Crinetics Pharmaceuticals (Nasdaq: CRNX) announced that its drug candidate atumelnant received FDA Orphan Drug Designation for treating congenital adrenal hyperplasia (CAH). Atumelnant is the first and only small molecule ACTH receptor antagonist in clinical development.The company reported positive Phase 2 results in January 2025, showing up to 80% mean reduction in androstenedione and improvements in clinical symptoms. Crinetics plans to initiate Phase 3 CALM-CAH study in adults and Phase 2/3 BALANCE-CAH study in pediatrics in H2 2025.The Orphan Drug Designation provides benefits including potential financial incentives and seven years of market exclusivity upon approval for treating this rare disease affecting fewer than 200,000 people in the U.S.

#CRNX Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

www.stocktitan.net/news/CRNX/crinetics-rece...

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline Crinetics Pharmaceuticals (Nasdaq: CRNX) announced it will present eight abstracts from its clinical development programs at ENDO 2025, taking place July 12-15, 2025, in San Francisco. The presentations will showcase data from multiple drug candidates across their endocrinology pipeline.Key highlights include long-term efficacy and safety data for PALSONIFY™ (paltusotine) in acromegaly, featuring four abstracts demonstrating consistent biochemical and symptom control in patients. The company will present Phase 2 trial results for atumelnant in congenital adrenal hyperplasia (CAH) through three abstracts, including data on adrenal volume reduction and androgens reduction.Additionally, Crinetics will present new data from its early-stage pipeline, including CRN12755 for Graves' hyperthyroidism and orbitopathy. The company will also host two sponsored science and innovation theaters focusing on acromegaly management.

#CRNX Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

www.stocktitan.net/news/CRNX/crinetics-to-s...

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Crinetics Pharmaceuticals (CRNX) reported Q1 2025 financial results and business updates. The company has $1.3B in cash and investments, expected to provide runway into 2029. Key highlights include: FDA review for paltusotine's NDA for acromegaly is on track with a PDUFA date of September 25, 2025. The EMA validated paltusotine's MAA with a potential decision in H1 2026. Q1 financials showed revenues of $0.4M, R&D expenses of $76.2M, and a net loss of $96.8M. The company plans to initiate multiple Phase 3 trials in H2 2025, including CALM-CAH for CAH treatment and CAREFNDR for carcinoid syndrome. An R&D Day is scheduled for June 26, 2025, to share updates on early-stage pipeline developments.

#CRNX Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CRNX/crinetics-phar...

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Crinetics Pharmaceuticals (CRNX) reported its Q4 and full year 2024 financial results, highlighting significant progress across operations. The company's NDA for paltusotine in acromegaly has a PDUFA date of September 25, 2025. Financial highlights include:- Net loss of $80.6M for Q4 2024 (vs $60.1M in Q4 2023)- Full-year 2024 net loss of $298.4M (vs $214.5M in 2023)- Strong cash position of $1.4B, providing runway into 2029- Expected 2025 cash burn of $340-380MThe company strengthened its leadership team with key appointments and reported positive results from Phase 2 studies of paltusotine in carcinoid syndrome and atumelnant in congenital adrenal hyperplasia. Four late-stage trials are planned for 2025, along with multiple IND filings for new development candidates.

#CRNX Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/CRNX/crinetics-phar...

Crinetics' CAH Drug Atumelnant Shows Remarkable 80% Biomarker Reduction in Phase 2 Trial Success Breakthrough Phase 2 results show Crinetics' atumelnant significantly reduced key CAH biomarkers by up to 80%, with strong safety profile and testosterone normalization in female patients.

#CRNX Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

www.stocktitan.net/news/CRNX/crinetics-anno...

Crinetics' Breakthrough Oral Acromegaly Drug Advances as FDA Accepts NDA for First-in-Class Treatment FDA sets September 2025 review date for paltusotine, potentially the first once-daily oral therapy for acromegaly. Key Phase 3 trial data supports this groundbreaking treatment.

#CRNX Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

#news #StockMarket #investing

www.stocktitan.net/news/CRNX/crinetics-anno...

#CRNX Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

www.stocktitan.net/news/CRNX/crinetics-phar...